CoreCap Advisors LLC increased its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 158.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 9,844 shares of the company’s stock after acquiring an additional 6,028 shares during the quarter. CoreCap Advisors LLC’s holdings in Eli Lilly and Company were worth $11,390,000 as of its most recent filing with the SEC.
A number of other hedge funds have also recently bought and sold shares of LLY. BlackRock Inc. increased its stake in shares of Eli Lilly and Company by 1.6% in the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after buying an additional 1,046,558 shares during the last quarter. State Street Corp raised its holdings in Eli Lilly and Company by 1.7% in the second quarter. State Street Corp now owns 36,215,754 shares of the company’s stock valued at $43,438,262,000 after acquiring an additional 605,752 shares in the last quarter. Bank of America Corp DE bought a new position in Eli Lilly and Company during the 2nd quarter valued at $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Eli Lilly and Company by 1.9% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock worth $8,647,153,000 after acquiring an additional 137,364 shares in the last quarter. Finally, Jennison Associates LLC grew its holdings in Eli Lilly and Company by 7.9% during the 2nd quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock worth $6,550,587,000 after acquiring an additional 400,538 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on LLY. The Goldman Sachs Group upped their target price on shares of Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the company a “buy” rating in a research note on Thursday, September 17th. Cantor Fitzgerald lifted their price target on Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the stock an “overweight” rating in a research note on Thursday. Morgan Stanley boosted their price objective on Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the company an “overweight” rating in a report on Wednesday. UBS Group set a $1,376.00 price objective on Eli Lilly and Company in a research note on Friday, August 7th. Finally, Citigroup lifted their target price on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $1,313.43.
Eli Lilly and Company News Summary
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: Higher analyst price target: Cantor Fitzgerald raised its target for Eli Lilly from $1,410 to $1,440 and maintained an “overweight” rating, implying substantial upside from recent levels. Benzinga report
- Positive Sentiment: Pipeline diversification remains a key bullish argument. Investors are highlighting next-generation obesity candidate retatrutide, which has shown greater weight loss in trials than Zepbound and could be filed with regulators in 2027. Lilly is also expanding its early-stage Alzheimer’s research and testing obesity drug eloralintide alongside birth control. Eli Lilly obesity business article
- Positive Sentiment: Growth extends beyond GLP-1 drugs. Jaypirca, Inluriyo and Retevmo could support oncology growth, while a new research and licensing agreement with InnoCare covers as many as five drug targets. Commentators argue that Lilly’s manufacturing expansion and broad pipeline create a growth flywheel beyond Mounjaro and Zepbound. Lilly oncology portfolio article
- Neutral Sentiment: Technical support is being watched. A move around the 50-day moving average may signal short-term stabilization, but technical indicators do not resolve the stock’s valuation or fundamental risks. LLY moving average analysis
- Negative Sentiment: Valuation and competition are weighing on sentiment. Lilly trades at a premium multiple, leaving the shares sensitive to pricing pressure, increased competition in obesity medicines and any slowdown in GLP-1 demand. New WHO childhood-obesity guidance may also create uncertainty around how these therapies are used in younger patients. WHO obesity guidance article
Insider Buying and Selling
In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock worth $15,958,170 in the last three months. 0.14% of the stock is owned by insiders.
Eli Lilly and Company Stock Performance
LLY stock traded down $18.95 during midday trading on Thursday, reaching $1,169.77. The company had a trading volume of 3,090,036 shares, compared to its average volume of 2,974,879. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The stock has a 50 day moving average price of $1,173.51 and a 200 day moving average price of $1,094.59. Eli Lilly and Company has a fifty-two week low of $783.85 and a fifty-two week high of $1,292.65. The firm has a market capitalization of $1.10 trillion, a PE ratio of 39.25, a P/E/G ratio of 1.42 and a beta of 0.46.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, beating the consensus estimate of $6.40 by $1.98. The company had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The business’s revenue was up 47.7% compared to the same quarter last year. During the same period in the prior year, the company earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Analysts anticipate that Eli Lilly and Company will post 36.66 earnings per share for the current year.
Eli Lilly and Company Profile
Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.
Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.
Featured Stories
- Five stocks we like better than Eli Lilly and Company
- Want Private-Market Access to Kalshi and Polymarket? Try This ETF
- Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds
- PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value
- Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
